2008-09-17 16:40:07 -
www.javelinpharmaceuticals.com - Investor Contacts: Javelin Pharmaceuticals, Inc. Rick Pierce, 617-349-4500 rpierce@javelinpharma.com or June Gregg jgregg@javelinpharma.com or Media Contacts: Richard Lewis Communications, Inc. Greg Tiberend, 212-827-0020 gtiberend@rlcinc.com or Megan Dubrowski mdubrowski@rlcinc.com Javelin Pharmaceuticals, Inc. (AMEX: JAV) announced today that Martin J. Driscoll, the Company's Chief Executive Officer, will provide a corporate overview at the 2008 UBS Global Life Sciences Conference at
the Grand Hyatt Hotel in New York City, Monday, September 22, 2008 at 12 Noon EDT.
The audio from the presentation will be webcast live from the UBS Investment Bank website - www.ibb.ubs.com and at
ir.javelinpharmaceuticals.com/events.cfm. A replay of the presentation will become available 3 hours after the live presentation and will remain available until October 25, 2008.
About Javelin Pharmaceuticals, Inc.:
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has one marketed drug in the UK and three drug candidates in US Phase 3 clinical development. For additional information about Javelin, please visit the company's website at
www.javelinpharmaceuticals.com.
Forward Looking Statement:
This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.
JAV-G
ΒΆ Presentation to be Webcast Live
